Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Four RNAi-Related Patent Applications: Oct 19, 2006

Title: Small Interference RNA Molecules for Modulating Superoxide Dismutase         
Number: 20060229268
Filed: Dec. 16, 2005
Lead Inventor: Daniel Benjamin, Alsgen
“The invention pertains to using double stranded ribonucleic acid molecules such as small interfering RNA molecules to target an SOD gene to interfere with gene expression and SOD protein production,” the patent application’s abstract states. “Methods are disclosed for inhibiting expression of a target protein in a subject with a neurological disorder by introducing a small interference ribonucleic acid molecule into the subject with the neurological disorder, such as amyotrophic lateral sclerosis.”

Title: Silencing of TGF-Beta Receptor Type II Expression by siRNA         
Number: 20060229266
Filed: Aug. 10, 2004 PCT Filed: Aug. 10, 2004
Lead Inventor: Nalin Kumar, University of Illinois at Chicago
The patent application, its abstract states, “is directed to siRNA-based silencing of the type II receptor of TGF-beta. SiRNAs that target this receptor abrogate the receptor protein and transcript, TGF-beta-mediated processes such as fibronectin assembly and cell migration also are inhibited and the molecules of the invention are efficacious in reducing the inflammatory response and matrix deposition. These findings show that siRNAs can be successfully delivered both in vitro and in vivo to regulate the TGF-beta type II receptor level and modulate wound response,” the abstract adds. “Methods and compositions exploiting the findings of the present invention have a wide-ranging application, extending from treatment of disorders of the eye to other organs and tissues throughout the body.”

Title: Novel Transgenic Methods Using Intronic RNA         
Number: 20060228800
Filed: March 31, 2006
Lead Inventor: Shi-Lung Lin, University of Southern California, Los Angeles
The invention “relates to a method and composition for generating an artificial intron and its components capable of producing microRNA molecules and thus inducing specific gene silencing effects through intracellular RNA interference mechanisms, and the relative utilization thereof,” the patent application’s abstract states. “The miRNA-producing intron so generated is not only useful for delivering desired miRNA function into the intron-mediated transgenic organisms or cells but also useful for suppressing unwanted gene function in the transgenic organisms or cells thereof. Furthermore, the derivative products of this novel man-made miRNA-producing intron have utilities in probing gene functions, validating drug targets, generating transgenic animals and gene-modified plants, developing anti-viral vaccines and treating as well preventing gene-related diseases.”

Title: Dicer-Interacting Proteins and Uses Thereof         
Number: 20060228361
Filed: April 14, 2005
Inventor: Craig Mello, University of Massachusetts Medical School

According to the patent application’s abstract, “Dicer interactors are disclosed as are methods to positively or negatively modulate Dicer activity. Uses of Dicer interactors as drug targets are featured. Also featured are uses of Dicer interactors and modulators of same to modulate various Dicer functions in vitro, in cell cultures, and in vivo.”

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.